OBJECTIVE: To evaluate the efficacy and safety of levetiracetam in the management of epilepsy in patients with glioma. DESIGN: A prospective study in hospitalized patients with a new diagnosis of glioma. SETTING: Department of Neurological Sciences and Visions, Spedali Civili of Brescia. PATIENTS: From March 1, 2006, until January 1, 2009, 176 consecutive patients (101 men and 75 women) with a first diagnosis of glioma were enrolled in the study. All patients with a diagnosis of epilepsy were treated with levetiracetam. MAIN OUTCOME MEASURES: Clinical, histological, and magnetic resonance imaging findings were analyzed. RESULTS: Age at the diagnosis of glioma ranged from 22 to 79 years (mean [SD], 57 [15] years; median, 59 years). Duration of the disease ranged from 27 days to 2(1/2) years (mean [SD], 13.7 [7.8] months; median, 13 months). Eighty-two patients received levetiracetam because of a diagnosis of epilepsy. At the last evaluation (May 1, 2009), 75 of 82 patients (91%) treated with levetiracetam were seizure free; in 2 of these patients, levetiracetam was withdrawn because of intolerable adverse effects. Prompt and long-lasting control of seizures was obtained in 49 of 82 patients (60%) with a dose of levetiracetam that ranged from 1500 to 3000 mg/d, and 9 (11%) of the treated patients needed an increase of levetiracetam dosage to 4000 mg/d to become seizure free. No laboratory abnormalities were observed in patients with concomitant chemotherapy. CONCLUSION: The results of this study provide good evidence that levetiracetam is efficacious and safe in patients with epilepsy due to glioma.
OBJECTIVE: To evaluate the efficacy and safety of levetiracetam in the management of epilepsy in patients with glioma. DESIGN: A prospective study in hospitalized patients with a new diagnosis of glioma. SETTING: Department of Neurological Sciences and Visions, Spedali Civili of Brescia. PATIENTS: From March 1, 2006, until January 1, 2009, 176 consecutive patients (101 men and 75 women) with a first diagnosis of glioma were enrolled in the study. All patients with a diagnosis of epilepsy were treated with levetiracetam. MAIN OUTCOME MEASURES: Clinical, histological, and magnetic resonance imaging findings were analyzed. RESULTS: Age at the diagnosis of glioma ranged from 22 to 79 years (mean [SD], 57 [15] years; median, 59 years). Duration of the disease ranged from 27 days to 2(1/2) years (mean [SD], 13.7 [7.8] months; median, 13 months). Eighty-two patients received levetiracetam because of a diagnosis of epilepsy. At the last evaluation (May 1, 2009), 75 of 82 patients (91%) treated with levetiracetam were seizure free; in 2 of these patients, levetiracetam was withdrawn because of intolerable adverse effects. Prompt and long-lasting control of seizures was obtained in 49 of 82 patients (60%) with a dose of levetiracetam that ranged from 1500 to 3000 mg/d, and 9 (11%) of the treated patients needed an increase of levetiracetam dosage to 4000 mg/d to become seizure free. No laboratory abnormalities were observed in patients with concomitant chemotherapy. CONCLUSION: The results of this study provide good evidence that levetiracetam is efficacious and safe in patients with epilepsy due to glioma.
Authors: Rohit R Das; Elinor Artsy; Shelley Hurwitz; Patrick Y Wen; Peter Black; Alexandra Golby; Barbara Dworetzky; Jong Woo Lee Journal: J Neurooncol Date: 2012-01-03 Impact factor: 4.130
Authors: Johan A F Koekkoek; Melissa Kerkhof; Linda Dirven; Jan J Heimans; Jaap C Reijneveld; Martin J B Taphoorn Journal: Neuro Oncol Date: 2015-03-25 Impact factor: 12.300
Authors: Andrea O Rossetti; Sandrine Jeckelmann; Jan Novy; Patrick Roth; Michael Weller; Roger Stupp Journal: Neuro Oncol Date: 2013-12-04 Impact factor: 12.300
Authors: Melissa Kerkhof; Janneke C M Dielemans; Melanie S van Breemen; Hanneke Zwinkels; Robert Walchenbach; Martin J Taphoorn; Charles J Vecht Journal: Neuro Oncol Date: 2013-05-16 Impact factor: 12.300